$6.25
-0.19-2.95%
At Close: -
$6.10
-0.15-2.40%
After Hours: Jul 22, 8:53 AM EDT
15 minutes delayed
Comments
Loading...
HOOKIPA Pharma
HOOKNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
HOOKIPA Pharma (NASDAQ:HOOK) Stock, Analyst Ratings, Price Targets, Forecasts
HOOKIPA Pharma Inc has a consensus price target of $4.97 based on the ratings of 8 analysts. The high is $11 issued by JMP Securities on November 10, 2021. The low is $0.5 issued by B of A Securities on December 2, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co., RBC Capital, and HC Wainwright & Co. on June 5, 2024, May 21, 2024, and April 26, 2024, respectively. With an average price target of $5.33 between HC Wainwright & Co., RBC Capital, and HC Wainwright & Co., there's an implied -12.57% downside for HOOKIPA Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
RBC Capital
Truist Securities
Morgan Stanley
B of A Securities
1calculated from analyst ratings
Analyst Ratings for HOOKIPA Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/05/2024 | Buy Now | -1.64% | HC Wainwright & Co. | Arthur He | $50 → $60 | Maintains | Buy | Get Alert |
| 05/21/2024 | Buy Now | -18.03% | RBC Capital | Brian Abrahams | $50 → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 04/26/2024 | Buy Now | -18.03% | HC Wainwright & Co. | Arthur He | $65 → $50 | Maintains | Buy | Get Alert |
| 03/25/2024 | Buy Now | -18.03% | RBC Capital | Brian Abrahams | $50 → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 03/25/2024 | Buy Now | 6.56% | HC Wainwright & Co. | Arthur He | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 01/30/2024 | Buy Now | -18.03% | RBC Capital | Brian Abrahams | $60 → $50 | Maintains | Outperform | Get Alert |
| 09/27/2023 | Buy Now | 14.75% | RBC Capital | Brian Abrahams | → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 09/06/2023 | Buy Now | -34.43% | Truist Securities | Asthika Goonewardene | → $40 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 6.56% | HC Wainwright & Co. | Arthur He | $80 → $65 | Maintains | Buy | Get Alert |
| 06/30/2023 | Buy Now | 14.75% | RBC Capital | Brian Abrahams | → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 06/05/2023 | Buy Now | -63.11% | Morgan Stanley | Vikram Purohit | $20 → $22.5 | Maintains | Equal-Weight | Get Alert |
| 05/12/2023 | Buy Now | 31.15% | HC Wainwright & Co. | Arthur He | → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2023 | Buy Now | -34.43% | Truist Securities | Asthika Goonewardene | $110 → $40 | Maintains | Buy | Get Alert |
| 03/16/2023 | Buy Now | 31.15% | HC Wainwright & Co. | Arthur He | → $80 | Reiterates | → Buy | Get Alert |
| 12/02/2022 | Buy Now | -91.8% | B of A Securities | Alec Stranahan | $60 → $5 | Downgrade | Buy → Underperform | Get Alert |
| 11/15/2022 | Buy Now | 14.75% | RBC Capital | Brian Abrahams | $80 → $70 | Maintains | Outperform | Get Alert |
| 08/23/2022 | Buy Now | 80.33% | Truist Securities | Asthika Goonewardene | $160 → $110 | Maintains | Buy | Get Alert |
| 08/11/2022 | Buy Now | -50.82% | SVB Leerink | Andrew Berens | $40 → $30 | Maintains | Outperform | Get Alert |
| 03/25/2022 | Buy Now | 47.54% | RBC Capital | Brian Abrahams | $110 → $90 | Maintains | Outperform | Get Alert |
| 02/17/2022 | Buy Now | 31.15% | HC Wainwright & Co. | Swayampakula Ramakanth | $150 → $80 | Maintains | Buy | Get Alert |
| 02/16/2022 | Buy Now | -34.43% | SVB Leerink | Andrew Berens | $30 → $40 | Maintains | Outperform | Get Alert |
| 11/12/2021 | Buy Now | -1.64% | Morgan Stanley | Vikram Purohit | → $60 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/11/2021 | Buy Now | 145.9% | HC Wainwright & Co. | Swayampakula Ramakanth | $210 → $150 | Maintains | Buy | Get Alert |
| 11/10/2021 | Buy Now | 63.93% | SVB Leerink | Andrew Berens | $280 → $100 | Maintains | Outperform | Get Alert |
| 11/10/2021 | Buy Now | 178.69% | RBC Capital | Brian Abrahams | $240 → $170 | Maintains | Outperform | Get Alert |
| 11/10/2021 | Buy Now | 80.33% | JMP Securities | Jason Butler | $250 → $110 | Maintains | Market Outperform | Get Alert |
| 08/18/2021 | Buy Now | 195.08% | Morgan Stanley | Vikram Purohit | $190 → $180 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for HOOKIPA Pharma (HOOK) stock?
The latest price target for HOOKIPA Pharma (NASDAQ:HOOK) was reported by HC Wainwright & Co. on June 5, 2024. The analyst firm set a price target for $6.00 expecting HOOK to fall to within 12 months (a possible -1.64% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for HOOKIPA Pharma (HOOK)?
The latest analyst rating for HOOKIPA Pharma (NASDAQ:HOOK) was provided by HC Wainwright & Co., and HOOKIPA Pharma maintained their buy rating.
When was the last upgrade for HOOKIPA Pharma (HOOK)?
There is no last upgrade for HOOKIPA Pharma
When was the last downgrade for HOOKIPA Pharma (HOOK)?
The last downgrade for HOOKIPA Pharma Inc happened on December 2, 2022 when B of A Securities changed their price target from $6 to $0.5 for HOOKIPA Pharma Inc.
When is the next analyst rating going to be posted or updated for HOOKIPA Pharma (HOOK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HOOKIPA Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HOOKIPA Pharma was filed on June 5, 2024 so you should expect the next rating to be made available sometime around June 5, 2025.
Is the Analyst Rating HOOKIPA Pharma (HOOK) correct?
While ratings are subjective and will change, the latest HOOKIPA Pharma (HOOK) rating was a maintained with a price target of $5.00 to $6.00. The current price HOOKIPA Pharma (HOOK) is trading at is $6.10, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.